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CASE STUDY
MALT lymphoma of the left biceps 
muscle: a rare case with an interesting 
presentation
Ipek Yonal‑Hindilerden1*, Fehmi Hindilerden2, Ibrahim Oner Dogan3 and Meliha Nalcaci1
Abstract 
Background: Extranodal marginal zone lymphoma (MZL), also called mucosa‑associated lymphoid tissue (MALT) 
lymphoma accounts for 7–8 % of non‑Hodgkin lymphomas (NHLs) and most commonly involves the stomach. How‑
ever, muscle involvement is very rare.
Case description: A 57‑year‑old woman was referred to our orthopaedics and traumatology clinic with a painful 
lump in the left arm. Physical examination revealed a red‑colored mass on the left arm and an enlarged lymph node 
measuring almost 5 cm in the left axillary region and 3 cm in the right axillary region. Tru‑cut biopsy of the mass in 
the left arm was consistent with MZL. The diagnosis was MALT lymphoma infiltrating the skeletal muscle (stage IIEA). 
R‑CHOP was started. Two additional infusions of rituximab were administered after the sixth cycle of R‑CHOP. Then, 
the patient received radiotherapy to the left arm at a dose of 30 Gy. After 1 year of follow‑up, the patient had no 
evidence of disease.
Discussion and evaluation: MALT lymphoma arises in a number of epithelial tissues. The clinical presentation of 
MALT lymphoma varies depending upon the tissue involved. To our knowledge, rare cases of MALT lymphoma of the 
skeletal muscle have been reported. Although the available literature suggests that primary skeletal muscle NHL with 
advanced stage is associated with poor prognosis, the case presented here suggests that rituximab based combina‑
tion therapy followed by radiotherapy can be an effective treatment for primary skeletal MALT lymphoma.
Conclusion: There is limited data regarding the prognosis and treatment of MALT lymphoma of the skeletal muscle. 
This case implies that rituximab based combination therapy followed by radiotherapy should be considered for the 
treatment of primary skeletal MALT lymphoma.
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Background
Extranodal marginal zone lymphoma (MZL), also called 
mucosa-associated lymphoid tissue (MALT) lymphoma 
accounts for 7–8 % of non-Hodgkin lymphomas (NHLs) 
and most commonly involves the stomach (Cavalli et al. 
2001). The most common manifestation sites of non-
gastric MALT lymphomas include the salivary glands, 
Waldeyer’s ring, the thyroid, the upper airways, the lung, 
the ocular adnexa, the breast, the liver, the urothelial sys-
tem, the skin, the dura and other soft tissues (Anderson 
et  al. 1997; Joshi et  al. 2012). Involvement of muscle is 
very rare and constitutes <1 % of all MALT lymphomas 
(Zucca et  al. 2003). Herein, we present an adult diag-
nosed with MALT lymphoma of the left biceps muscle 
with enlarged distant lymph nodes, who was treated with 
combined chemo-immunotherapy and radiotherapy and 
remains disease free after 1 year of follow up.
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Case description
A 57-year-old woman was referred to our orthopaedics 
and traumatology clinic with a painful lump in the left 
arm. Physical examination revealed a red-colored mass 
on the left arm (Fig. 1) and an enlarged lymph node meas-
uring almost 5  cm in the left axillary region and 3  cm 
in the right axillary region. Magnetic resonance imag-
ing (MRI) of the left arm showed a 17.7 × 5.8 × 7.3 cm 
enhancing mass in the medial aspect of the left biceps 
muscle and multiple left axillary lymph nodes with a 
maximal diameter of 4.8  ×  3.4  cm. Tru-cut biopsy of 
the mass in the left arm revealed infiltration of atypi-
cal centrocyte-like cells with or without clear cytoplasm 
with a Kİ-67 proliferative index of 30 % and stained posi-
tive for CD20 and pax-5 and negative for CD5, CD10 
and bcl-2, positive for CD21 in the follicular dendritic 
cell network, findings consistent with MZL (Figs.  2, 3). 
With a final diagnosis of MALT lymphoma infiltrating 
the skeletal muscle, she was referred to our hematology 
department. The patient had no B symptoms. Her hemo-
globin was 12  g/dL, white blood cell count 8420/mm3 
with a lymphocyte count 2800/mm3 and platelet count 
was 292,000/mm3. On biochemical tests, the following 
were abnormal: lactate dehydrogenase 1218 U/L (240-
480), CRP 40 mg/L (0–5), ESR 120 mm/h (0–20) and β2-
microglobulin level 3.52  mg/L (0.7–1.8). Serum protein 
electrophoresis showed polyclonal gammopathy with an 
increased component with gamma fraction of 1.51 g/dL. 
Hepatitis B, C and HIV infection serology and screen-
ing for autoimmune disorders were negative. Bone mar-
row biopsy was negative. Cervical computed tomography 
(CT), and abdominopelvic CT were normal. On chest 
CT, there were multiple left axillary lymph nodes with 
a maximal diameter of 5  cm and a 3  cm right axillary 
lymph node. Diagnosed with stage 2 disease, R-CHOP 
(rituximab, cyclophosphamide, doxorubicin, vincristine, 
methylprednisolone) was initiated. After 6 cycles, mass 
in the medial aspect of the left biceps muscle regressed 
to a size of 3.2 × 1.1 × 1 cm and bilateral axillary lymph 
nodes totally disappeared. Two additional infusions of 
rituximab were administered after the sixth cycle of 
R-CHOP. Subsequently, the patient underwent radiother-
apy to the left arm at a dose of 30 Gy. Physical examina-
tion 1 and 6 months and 1 year after treatment revealed 
no palpable residual mass, swelling or skin erythema. 
6-months and 1-year after completion of treatment, MRI 
of the left humerus demonstrated no evidence of residual 
disease. Also, cervical, chest and abdominopelvic CT at 
1 year showed no disease involvement.
Discussion and evaluation
MALT lymphoma arises in a number of epithelial tis-
sues, including the stomach, salivary gland, lung, small 
bowel and thyroid. MALT lymphoma constitutes about 
5 % of all NHLs and almost 50 % of all gastric lympho-
mas (Armitage and Weisenburger 1998). Persistent 
antigenic stimulation due to autoimmune processes or 
chronic infectious conditions, such as H pylori gastritis, 
Sjögren syndrome and Hashimoto thyroiditis predispose 
to development of MALT (Isaacson and Du 2004). Data 
from epidemiological and molecular studies favor a mul-
tistage theory (Zucca et  al. 1998; Seydel et  al. 2003). In 
gastric MALT lymphomas which have been extensively 
studied, it is considered that the molecular mechanism 
involves the stimulation of antigen receptor by autoanti-
gen and co-stimulatory molecule CD40 by H pylori-spe-
cific T cells. MALT lymphoma develops as marginal zone 
memory B cells undergo somatic mutation and efface the 
normal B cell population (Hamoudi et al. 2010).
The clinical presentation of extranodal MZL var-
ies depending upon the tissue involved. Stomach is the 
most common site of involvement (Cavalli et  al. 2001). 
Involved field radiation therapy for treatment of stom-
ach MALT has been well established, yielding excellent 
outcomes with over 90 % local control reported in most 
studies (Tsang et al. 2001; Tsai et al. 2007). Treatment of 
nongastric MALT lymphomas is much less defined in the 
literature compared to gastric MALT lymphomas. To our 
knowledge, rare cases of MALT lymphoma of the skeletal 
muscle have been reported (Bozzola et al. 2005; Gill et al. 
2006; Edwards-Bennett et  al. 2011). The involvement 
sites of previously reported MALT lymphomas of skel-
etal muscle include the distal biceps and proximal triceps 
muscles in one case, right triceps muscle in one case and 
quadriceps muscle in another case (Bozzola et  al. 2005; 
Gill et al. 2006; Edwards-Bennett et al. 2011). One pub-
lished case presented with stage IV disease with pulmo-
nary involvement. That patient was treated initially with 
6 cycles of CHOP and with radiation therapy for local Fig. 1 The appearance of mass and skin erythema at the left arm
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Fig. 2 Tru‑cut biopsy of the mass in the left arm revealed infiltration of atypical centrocyte‑like cells with or without clear cytoplasm (a; ×40),  
(b; ×400)
Fig. 3 Immunohistochemical features of the infiltrated cells in the left arm expressed CD20 (a; ×200), stained negative for CD5 (b; ×100), stained 
positive for CD21 in follicular dendritic cell network (c; ×100), 30 % positivity for Ki‑67 (d; ×200)
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relapse 4  years later, and finally with chemotherapy for 
a second relapse (Gill et  al. 2006). The aforementioned 
case suggests that primary skeletal lymphoma shows 
more aggressive behavior, presents as advanced stage, 
and is associated with poor outcome (Gill et  al. 2006). 
On the other hand, one previous case presented with 
early stage (IE) and was treated with involved field radia-
tion therapy resulting in complete response (Edwards-
Bennett et  al. 2011). The available data is very limited 
and probably suggests that primary skeletal muscle NHL 
with advanced stage is associated with poor prognosis, 
the case presented here suggests that rituximab based 
combination therapy followed by radiotherapy can be an 
effective option for treatment of primary skeletal MALT 
lymphoma. Yet, it needs to be mentioned that 1 year-fol-
low up is too short to support the long term effectiveness 
of this approach for an indolent lymphoma.
Conclusion
In conclusion, a 57-year-old woman with MALT lym-
phoma infiltrating the skeletal muscle was successfully 
managed by 6 cycles of R-CHOP plus two additional 
infusions of rituximab and radiotherapy. There is limited 
reported data regarding the prognosis and treatment of 
MALT lymphoma of the skeletal muscle. We conclude 
that rituximab based combination therapy and subse-
quent radiotherapy can be an effective treatment for pri-
mary skeletal MALT lymphoma.
Abbreviations
MZL: extranodal marginal zone lymphoma; MALT: mucosa‑associated 
lymphoid tissue; NHLs: non‑Hodgkin lymphomas; MRI: magnetic resonance 
imaging.
Authors’ contributions
All the authors made a contribution to the preparation of the manuscript. IYH, 
FH and MN managed the patient. IOD made the pathological diagnosis. IYH 
wrote her case report with other coauthors. FH and MN reviewed the case. All 
authors read and approved the final manuscript.
Author details
1 Division of Hematology, Department of Internal Medicine, Istanbul Medical 
Faculty, Istanbul University, Istanbul, Turkey. 2 Hematology Clinic, Istanbul 
Bakırkoy Sadi Konuk Training and Research Hospital, Istanbul, Turkey. 3 Depart‑
ment of Pathology, Istanbul Medical Faculty, Istanbul University, Istanbul, 
Turkey. 
Acknowledgements
We would like to thank the Pathology Laboratory in Istanbul University, Istan‑
bul Medical Faculty for assistance with sample processing.
Competing interests
The authors declare that they have no competing interests.
Consent statement
Written informed consent was obtained from the patient for publication of 
this case report and any accompanying images.
Received: 12 May 2016   Accepted: 20 July 2016
References
Anderson J, Armitage JO, Berger F, Cavalli F, Chan WC, Close J, Coiffier B, Con‑
nors J, Diebold J, Gascoyne R, Harris N (1997) A clinical evaluation of the 
International Lymphoma Study Group classification of non‑Hodgkin’s 
lymphoma: the Non‑Hodgkin’s Lymphoma Classification Project. Blood 
89:3909–3918
Armitage JO, Weisenburger DD (1998) New approach to classifying non‑Hodg‑
kin’s lymphomas: clinical features of the major histologic subtypes. Non‑
Hodgkin’s Lymphoma Classification Project. J Clin Oncol 16:2780–2795
Bozzola C, Boldorini R, Ramponi A, Monga G (2005) Fine needle aspiration 
cytology in the diagnosis of non‑Hodgkin’s lymphomas of the muscle: a 
report of 2 cases. Acta Cytol 49:213–218
Cavalli F, Isaacson PG, Gascoyne RD, Zucca E (2001) MALT lymphomas. Hema‑
tol Am Soc Hematol Educ Program 2001:241–258
Edwards‑Bennett SM, Straus D, Athanasian EA, Yahalom J (2011) Extranodal 
MALT lymphoma of the right triceps muscle following influenza vaccine 
injection: a rare case with an interesting presentation. ISRN Hematol 
2011:617293. doi:10.5402/2011/617293
Gill SI, Gibbs SD, Hicks RJ, Seymour JF (2006) Primary skeletal muscle marginal 
zone lymphoma with persistent tissue tropism and PET‑avidity. Leuk 
Lymphoma 47:117–120
Hamoudi RA, Appert A, Ye H, Ruskone‑Fourmestraux A, Streubel B, Chott A 
et al (2010) Differential expression of NF‑kappa B target genes in MALT 
lymphoma with and without chromosome translocation: insights into 
molecular mechanism. Leukemia 24:1487–1497
Isaacson PG, Du MQ (2004) MALT lymphoma: from morphology to molecules. 
Nat Rev Cancer 4:644–653
Joshi M, Sheikh H, Abbi K, Long S, Sharma K, Tulchinsky M et al (2012) Marginal 
zone lymphoma: old, new, targeted, and epigenetic therapies. Ther Adv 
Hematol 3:275–290. doi:10.1177/2040620712453595
Seydel J, Ullrich A, Bender R, Fischbach W, Blettner M (2003) Helicobacter pylori 
and carcinogenesis of gastric B‑cell lymphomas. Int J Cancer 104:646–649
Tsai HK, Li S, Ng AK, Silver B, Stevenson MA, Mauch PM (2007) Role of radiation 
therapy in the treatment of stage I/II mucosa‑associated lymphoid tissue 
lymphoma. Ann Oncol 18:672–678
Tsang RW, Gospodarowicz MK, Pintilie M, Bezjak A, Wells W, Hodgson DC et al 
(2001) Stage I and IIMALT lymphoma: results of treatment with radio‑
therapy. Int J Radiat Oncol Biol Phys 50:1258–1264
Zucca E, Bertoni F, Roggero E, Bosshard G, Cazzaniga G, Pedrinis E et al (1998) 
Molecular analysis of the progression from Helicobacter pylori‑associated 
chronic gastritis to mucosa‑associated lymphoid‑tissue lymphoma of the 
stomach. N Engl J Med 338:804–810
Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK, 
International Extranodal Lymphoma Study Group et al (2003) Nongastric 
marginal zone B‑cell lymphoma of mucosa‑associated lymphoid tissue. 
Blood 101:2489–2495
